Folate-mediated targeting of T cells to tumors

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1219-1231

  Roy, Edward J ^a   Gawlick, Ute ^a   Orr, Brent A ^a   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Antigen presenting cells; Folate antibody conjugates; Immunotherapy; Macrophages; T cell responses

Indexed keywords

ANTIBODIES; CELLS; DRUG DOSAGE; HISTOLOGY; TUMORS; VACCINES;

ANTIGEN PRESENTING CELLS (APC); FOLATE-RECEPTOR (FR); PEPTIDE-MAJOR HISTOCOMPATIBILITY COMPLEX (MHC); T CELLS;

BIOMEDICAL ENGINEERING;

ALPHA INTERFERON; CANCER ANTIBODY; FOLATE RECEPTOR; FOLIC ACID; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MEMBRANE RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TUMOR; TUMOR CELL; TUMOR MODEL;

EID: 1942439007     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.006     Document Type: Article

References (87)

1. Gorer P.A. The genetic and antigenic basis of tumor transplantation. J. Pathol. Bacteriol. 44:1937;691-697.
2. Zinkernagel R.M., Doherty P.C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature. 251:1974;547-548.
3. Boon T., Old L.J. Cancer tumor antigens. Curr. Opin. Immunol. 9:1997;681-683.
4. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287.
5. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature. 411:2001;380-384.
6. Davis S.J., Ikemizu S., Evans E.J., Fugger L., Bakker T.R., van der Merwe P.A. The nature of molecular recognition by T cells. Nat. Immunol. 4:2003;217-224.
7. Cresswell P., Lanzavecchia A. Antigen processing and recognition. Curr. Opin. Immunol. 13:2001;11-12.
8. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Ann. Rev. Immunol. 14:1996;233-258.
9. Arcaro A., Gregoire C., Bakker T.R., Baldi L., Jordan M., Goffin L., Boucheron N., Wurm F., van der Merwe P.A., Malissen B., Luescher I.F. CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. J. Exp. Med. 194:2001;1485-1495.
10. Holler P.D., Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 18:2003;255-264.
11. Kranz D.M., Tonegawa S., Eisen H.N. Attachment of an anti-receptor antibody to nontarget cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 81:1984;7922-7926.
12. Liu M.A., Kranz D.M., Kurnick J.T., Boyle L.S., Levy R., Eisen H.N. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 82:1985;8648-8652.
13. Staerz U.D., Kanagawa O., Bevan M.J. Hybrid antibodies can target sites for attack by T cells. Nature. 314:1985;628-631.
14. Fanger M.W., Drakeman D.L. Bispecific antibodies. Drug News Perspect. 8:1995;133-137.
15. Segal D.M., Weiner G.J., Weiner L.M. Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11:1999;558-562.
16. Bluestone J.A., Bruce D.S., Newell K.A. Activation of T cells in vivo using anti-CD3 and staphylococcal enterotoxins. Int. J. Cancer Suppl. 7:1992;39-41.
17. Kroesen B.J., Bakker A., van Lier R.A., The H.T., de Leij L. Bispecific antibodymediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res. 55:1995;4409-4415.
18. Renner C., Jung W.F., Sahin U., Vanlier R., Pfreundschuh M. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur. J. Immunol. 25:1995;2027-2033.
19. Coulie P.G., Bruggen P. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15:2003;131-137.
20. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:2003;138-147.
21. Finn O.J. Cancer vaccines: between the idea and reality. Nat. Rev. Immunol. 3:2003;630-641.
22. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:2001;769-779.
23. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
24. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:2002;16168-16173.
25. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R.M., Ohashi P.S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:1997;645-653.
26. Theobald M., Biggs J., Hernandez J., Lustgarten J., Labadie C., Sherman L.A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:1997;833-841.
27. Sherman L.A., Morgan D.J., Nugent C.T., Hernandez F.J., Kreuwel H.T., Murtaza A., Ko A., Biggs J. Self-tolerance and the composition of T cell repertoire. Immunol. Res. 21:2000;305-313.
28. Kessels H.W., van Den Boom M.D., Spits H., Hooijberg E., Schumacher T.N. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA. 97:2000;14578-14583.
29. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA. 97:2000;5387-5392.
30. Schumacher T.N. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2:2002;512-519.
31. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2:2001;957-961.
32. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., Stauss H.J., Theobald M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:2001;962-970.
33. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA. 86:1989;10024-10028.
34. Hwu P., Yang J.C., Cowherd R., Treisman J., Shafer G.E., Eshhar Z., Rosenberg S.A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:1995;3369-3373.
35. Pinthus J.H., Waks T., Kaufman-Francis K., Schindler D.G., Harmelin A., Kanety H., Ramon J., Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2003;2470-2476.
36. Coney L.R., Tomassetti A., Carayannopoulos L., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R. Jr. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51:1991;6125-6132.
37. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R. Jr., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
38. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
39. Antony A.C. Folate receptors. Annu. Rev. Nutr. 16:1996;501-521.
40. Mezzanzanica D., Garrido M.A., Neblock D.S., Daddona P.E., Andrew S.M., Zurawski V.R. Jr., Segal D.M., Wunderlich J.R. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51:1991;5716-5721.
41. Boerman O.C., Tibben J.G., Massuger L.F., Claessens R.A., Corstens F.H. Tumour targeting of the anti-ovarian carcinoma×anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Anticancer Res. 15:1995;2169-2174.
42. Rund L.A., Cho B.K., Manning T.C., Holler P.D., Roy E.J., Kranz D.M. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer. 83:1999;141-149.
43. -/- mice. J. Immunol. 159:1997;4665-4675.
44. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
45. Brigle K.E., Spinella M.J., Westin E.H., Goldman I.D. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem. Pharmacol. 47:1994;337-345.
46. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., Roy E.J. Conjugates of folate and anti-T cell receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA. 92:1995;9057-9061.
47. Van Dyke T., Finlay C., Levine A.J. A comparison of several lines of transgenic mice containing the SV early genes. Cold Spring Harbor Symp. Quant. Biol. 50:1985;671-678.
48. Van Dyke T.A., Finlay C., Miller D., Marks J., Lozano G., Levine A.J. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J. Virol. 61:1987;2029-2032.
49. Patrick T.A., Kranz D.M., Van Dyke T.A., Roy E.J. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J. Neuro-Oncol. 32:1997;111-123.
50. Schell T.D., Mylin L.M., Georgoff I., Teresky A.K., Levine A.J., Tevethia S.S. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. 73:1999;5981-5993.
51. Schell T.D., Tevethia S.S. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J. Immunol. 167:2001;6947-6956.
52. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G., Pupa S.M., Regazzoni M., Tabliabue E., Colnaghi M.I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer. 39:1987;297-303.
53. Ferrini S., Cambiaggi A., Cantoni C., Canevari S., Mezzanzanica D., Colnaghi M.I., Moretta L. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int. J. Cancer. 7:1992;15-18.
54. Lamers C.H., Gratama J.W., Warnaar S.O., Stoter G., Bolhuis R.L. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T lymphocytes. Int. J. Cancer. 60:1995;450-457.
55. Luiten R.M., Warnaar S.O., Sanborn D., Lamers C.H., Bolhuis R.L., Litvinov S.V., Zurawski V.R. Jr., Coney L.R. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J. Immunother. 20:1997;496-504.
56. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.
57. Patrick T.A., Kranz D.M., Zachary J.F., Roy E.J. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer. 78:1998;470-479.
58. Cho B.K., Roy E.J., Patrick T.A., Kranz D.M. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjug. Chem. 8:1997;338-346.
59. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., Peace D., Jollife L.K., Haverty T., Bluestone J.A., Thistlethwaite J.R. Jr. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 68:1999;608-616.
60. Bottero F., Tomassetti A., Canevari S., Miotti S., Menard S., Colnaghi M.I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 53:1993;5791-5796.
61. Rosenberg S.A. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol. Today. 9:1988;58-62.
62. Overwijk W.W., Theoret M.R., Restifo N.P. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6:(Suppl. 1):2000;S76-80.
63. Waldmann T.A., Dubois S., Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 14:2001;105-110.
64. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 9:2003;269-277.
65. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:2003;133-146.
66. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52:2003;133-144.
67. Mortarini R., Borri A., Tragni G., Bersani I., Vegetti C., Bajetta E., Pilotti S., Cerundolo V., Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res. 60:2000;3559-3568.
68. Roy E.J., Gawlick U., Orr B.A., Rund L.A., Webb A.G., Kranz D.M. IL-12 treatment of endogenously arising murine brain tumors. J. Immunol. 165:2000;7293-7299.
69. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 270:1995;908.
70. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., Sosman J.A., Dutcher J.P., Vogelzang N.J., Ryan J.L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
71. de Visser K.E., Cordaro T.A., Kessels H.W., Tirion F.H., Schumacher T.N., Kruisbeek A.M. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167:2001;3818-3828.
72. Ohlen C., Kalos M., Hong D.J., Shur A.C., Greenberg P.D. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2001;2863-2870.
73. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., Roederer M., Davis M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
74. Townsend S.E., Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 259:1993;368-370.
75. Blanco B., Holliger P., Alvarez-Vallina L. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Ther. 9:2002;275-281.
76. Mazzoni A., Mezzanzanica D., Jung G.R., Wolf H., Colnaghi M.I., Canevari S. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res. 56:1996;5443-5449.
77. Grosse-Hovest L., Brandl M., Dohlsten M., Kalland T., Wilmanns W., Jung G. Tumor growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Int. J. Cancer. 80:1999;138-144.
78. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:1996;747-752.
79. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;1609-1616.
80. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA. 88:1991;5572-5576.
81. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. Biol. Chem. 268:1993;24847-24854.
82. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target. 2:1994;101-112.
83. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptormediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
84. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
85. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3312-3318.
86. Turk M.J., Breur G.J., Widmer W.R., Paulos C.M., Xu L.C., Grote L.A., Low P.S. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 46:2002;1947-1955.
87. Lu Y., Low P.S. Targeted immunotherapy of cancer: development of antibody-induced cellular immunity. J. Pharm. Pharmacol. 55:2003;163-167.